Want to see RNXT full AI Analyst Report?
RNXT Stock Chart & Stats
$0.86
$0.08(9.14%)
At close: 4:00 PM EDT
$0.86
$0.08(9.14%)
Day’s Range― - ―
52-Week Range$0.70 - $1.45
Previous CloseN/A
Volume351.25K
Average Volume (3M)288.82K
Market Cap
$43.17M
Enterprise Value$26.24
Total Cash (Recent Filing)$12.36M
Total Debt (Recent Filing)$186.00K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 12, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding45,052,708
10 Day Avg. Volume236,040
30 Day Avg. Volume288,821
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)5.47
Price to Sales (P/S)26.43
P/FCF Ratio-2.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside713.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$3.21M
Bulls Say, Bears Say
Bulls Say
Strong Gross Margins / Unit EconomicsSustained high gross margins (85% Q1, ~79% TTM) indicate attractive unit economics for the RenovoCath platform. Durable margin advantage supports profitability as procedural volume scales, provides pricing and COGS flexibility, and lowers the incremental cash needed per additional procedure.
Commercial Rollout Momentum And AdoptionRapid growth in active centers (5→16 in ~18 months) and a 48-center pipeline show durable commercial adoption driven by physician advocacy and repeat orders. A broadening clinical footprint reduces single-center concentration risk and supports recurring device/procedure revenue as centers convert.
Very Low Leverage And Stronger Equity BaseMinimal debt burden reduces interest and refinancing risk and preserves financial flexibility. The material equity increase (and recent ~$10M private placement noted in calls) strengthens the balance sheet, giving management runway to pursue commercialization and trial completion without heavy near-term leverage.
Bears Say
Persistent Negative Operating Cash FlowConsistent ~-$11M annual cash burn is a durable constraint on the business, forcing reliance on external funding unless revenue scales materially. Persistent negative cash flow limits reinvestment capacity, risks dilution from future financings, and could slow manufacturing and commercialization efforts if conversions lag.
Modest Absolute Revenue Base And Concentration RiskWhile growth rates are strong, the small absolute revenue base means margins and cash flow are fragile: fixed SG&A/R&D costs loom large and quarterly 'chunkiness' from center approvals can cause volatile cash generation. Durable scaling is required to absorb expenses and prove sustainable profitability.
Nasdaq Listing Compliance RiskOngoing listing compliance pressure is a structural governance and capital-access risk. Potential delisting or remediation actions could distract management, reduce liquidity and institutional interest, and complicate future financings or strategic partnerships if unresolved by the deadline.
RenovoRx News
RNXT FAQ
What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $0.70 and its highest was $1.45 in the past 12 months.
What is RenovoRx’s market cap?
RenovoRx’s market cap is $43.17M.
When is RenovoRx’s upcoming earnings report date?
RenovoRx’s upcoming earnings report date is Aug 12, 2026 which is in 5 days.
How were RenovoRx’s earnings last quarter?
RenovoRx released its earnings results on May 14, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.01.
Is RenovoRx overvalued?
According to Wall Street analysts RenovoRx’s price is currently Undervalued.
Does RenovoRx pay dividends?
RenovoRx does not currently pay dividends.
What is RenovoRx’s EPS estimate?
RenovoRx’s EPS estimate is -0.07.
How many shares outstanding does RenovoRx have?
RenovoRx has 45,052,708 shares outstanding.
What happened to RenovoRx’s price movement after its last earnings report?
RenovoRx reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -4.094%.
Which hedge fund is a major shareholder of RenovoRx?
Currently, no hedge funds are holding shares in RNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (713.95% Upside)
$7.00 (713.95% Upside)
Blogger Sentiment
Bearish
RNXT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $19.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.80%
Trailing 12-Months
Company Description
RenovoRx
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
RNXT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful operational milestones: record quarterly revenue with very high gross margins, rapid expansion of active centers and a sizable prospect pipeline, near-completion of the pivotal Phase III trial, and a successful $10M private placement providing runway into H2 2027. Offsetting factors include still-modest absolute revenue, sizable operating expenses (R&D $1.2M; SG&A ~$2.7M), remaining trial and event targets to achieve, and timing/convertibility risk of pipeline centers. Overall the positive execution on commercial scaling, healthy margins, and a reinforced balance sheet materially outweigh the near-term risks described.View all RNXT earnings summariesRNXT Stock 12 Month Forecast
Average Price Target
$7.00
▲(713.95% Upside)
Technical Analysis
Immutep
―
Karyopharm Therapeutics
―
TScan Therapeutics
―
Xilio Therapeutics
―
Radiopharm Theranostics Limited Sponsored ADR
―
Ownership Overview
3.53% Insiders
3.91% Mutual Funds
0.24% Other Institutional Investors
89.18% Public Companies and
Individual Investors